What We're Reading: Page 90
Industry reads hand-picked by our editors
Sep 13, 2023
-
AP News
Popular nasal decongestant doesn’t actually relieve congestion, FDA advisers say
-
Axios
Biden admin previews defense of drug price negotiations
-
Fierce Biotech
Roche places ‘stronger gates’ on phase 3 pipeline to limit failures
-
The Times
AstraZeneca’s drugs chief Sir Mene Pangalos cures his work-life balance
Sep 12, 2023
-
Science
Her work paved the way for blockbuster obesity drugs. Now, she’s fighting for recognition
-
Reuters
AstraZeneca seeks to calm CEO speculation after shares drop
-
C&EN
Long COVID: The hunt for causes and cures
-
AP News
Patients need doctors who look like them. Can medicine diversify without affirmative action?
Sep 11, 2023
Sep 08, 2023
-
Fierce Pharma
Patent cliffs and divestitures point to an uptick in M&A
-
Nature Medicine
Pioneering the path to NASH biomarker approval
-
Healthcare Dive
‘Revolving door’ between HHS and industry could influence regulation, study says
Sep 07, 2023
-
The Atlantic
We Have No Drugs to Treat the Deadliest Eating Disorder
-
FirstWord Pharma
J&J scraps late-stage pulmonary hypertension study of macitentan
-
Gizmodo
Counterfeit Pills Are Becoming Deadlier in America
-
The Wall Street Journal
Health-Insurance Costs Are Taking Biggest Jumps in Years
Sep 06, 2023
-
CNBC
Judge withdraws from Medicare drug price case after stock ownership is revealed
-
Science
As shutdown looms, will U.S. Congress cut spending and restrict research?
-
Boston Business Journal
As Needham biotech struggles with FDA, patients with an ultra-rare disease are waiting
-
The Washington Post
Rising cases in Southeast could be start of U.S. RSV season, CDC warns
Sep 05, 2023
-
The Wall Street Journal
How Novartis’s CEO Learned From His Mistakes and Got Help From an Unlikely Quarter
-
Reuters
Wegovy makes UK weight-loss debut even as Novo struggles with supplies
-
Fierce Biotech
BMS pays Zenas $50M for some rights to ex-Xencor autoimmune drug
-
The New York Times
A Huge Threat to the U.S. Budget Has Receded. And No One Is Sure Why.
Previous
